Why markets already priced in a vaccine approval, stellar gains from AIM stocks in 2020, retail’s latest challenge and dealing with NS&I’s punishing rate cuts
The UK’s status as the first country in the world to approve Pfizer’s Covid vaccine failed to move stock markets on the day of the news. Listen to the podcast to find out why markets reacted in this way. Tom Sieber from Shares magazine joins the show to discuss the reasons why the AIM market has done nearly as well as…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from AJ Bell Money & Markets
See all episodes →
Similar episodes from other shows
More like AJ Bell Money & Markets →
Will the vaccine value rally continue for investors?
One ISA to rule them all
Stockmarket sentiment and doom-mongers
FTSE vs Wall Street: Can the UK compete?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.